Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

16 Sökresultat.
Relevans Bedömning Nya först Gamla först

Corticosteroid Medication Week 38 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 38

- 2017-07-14 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Week 38/ Early Withdrawal visit. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 32 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 32

- 2017-07-12 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 28 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 28

- 2017-07-12 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Week 28. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 24 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 24

- 2017-07-12 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Week 24. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 20 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 20

- 2017-07-12 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Week 20. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 16 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 16

- 2017-07-12 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Week 16. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 12 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 12

- 2017-07-10 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Week 12. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Weeks 9- 11 Mepolizumab HES NCT00086658 - Corticosteroid Medication Weeks 9- 11

- 2017-07-10 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Weeks 9- 11. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 8 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 8

- 2017-07-09 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Week 8. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Weeks 5 - 7 Mepolizumab HES NCT00086658 - Corticosteroid Medication Weeks 5 - 7

- 2017-07-09 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Weeks 5 - 7. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 4 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 4

- 2017-06-11 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Week 4. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 1-3 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 1-3

- 2017-06-11 - 1 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: Corticosteroid Medication
Study part: Corticosteroid Medication Week 1-3. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial